PharmaCyte Biotech Inc. (PMCB): Price and Financial Metrics
PMCB Price/Volume Stats
Current price | $2.37 | 52-week high | $3.23 |
Prev. close | $2.44 | 52-week low | $1.92 |
Day low | $2.29 | Volume | 34,500 |
Day high | $2.50 | Avg. volume | 26,118 |
50-day MA | $2.16 | Dividend yield | N/A |
200-day MA | $2.34 | Market Cap | 20.06M |
PMCB Stock Price Chart Interactive Chart >
PharmaCyte Biotech Inc. (PMCB) Company Bio
PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
Latest PMCB News From Around the Web
Below are the latest news stories about PHARMACYTE BIOTECH INC that investors may wish to consider to help them evaluate PMCB as an investment opportunity.
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024PharmaCyte Biotech just reported results for the second quarter of 2024. |
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company’s first investment in externally dev |
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unme |
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box TechnologyLAS VEGAS, October 31, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In |
PharmaCyte Biotech Announces Final Results of Tender OfferLAS VEGAS, June 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and was funded entirely through the Company’s cash on han |
PMCB Price Returns
1-mo | 12.86% |
3-mo | 9.72% |
6-mo | 12.86% |
1-year | -16.84% |
3-year | -90.87% |
5-year | -96.75% |
YTD | 9.72% |
2023 | -26.28% |
2022 | 17.20% |
2021 | -75.12% |
2020 | -83.46% |
2019 | 9.46% |
Loading social stream, please wait...